Aethlon Medical, Inc. announced on June 18, 2025, the successful treatment of the second patient in its Australian safety, feasibility, and dose-finding clinical trial of the Hemopurifier. The patient received treatment on June 11, 2025, at Royal North Shore Hospital/University of Sydney.
Both the first and second participants in the initial cohort completed their 4-hour Hemopurifier treatments without device deficiencies or immediate complications. As of June 10, 2025, both patients also completed the pre-specified 7-day safety follow-up period.
The completion of treatments for two patients moves the trial closer to a safety review by an independent Data Safety Monitoring Board (DSMB), which will convene after the treatment of a third patient in the cohort. The DSMB's recommendation will determine advancement to the second treatment cohort.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.